Exploring healthcare providers' experiences with specialty medication and limited distribution networks.
Megan E PeterAutumn D ZuckermanElizabeth CherryDavid G SchlundtKemberlee BonnetNisha ShahTara N KelleyPublished in: PloS one (2022)
Integrated health-system specialty pharmacies (IHSSP) have shown high medication access, adherence, and provider satisfaction. The goal of this study was to explore healthcare providers' experiences with specialty medications distributed via Limited Distribution Networks (LDN) that do not include IHSSPs. We investigated healthcare providers' perceived impact of LDNs on clinic workflow, clinical practice, and patient outcomes. Interviews and focus groups were conducted with fourteen healthcare providers from four outpatient specialty clinics at an academic health system with an IHSSP. Qualitative analysis using an iterative inductive/deductive approach of coded transcripts was used to identify themes. Participants discussed requirements and barriers to communicating with insurance providers, drug manufacturers, and external pharmacies; time and effort required to navigate LDNs and impact on workload and clinic workflow; financial awareness of medication costs and methods for communication about financial information with patients; and advocating for patients to ensure access to necessary therapy and avoid missed doses or treatment lapse. Participants reported barriers to navigating LDNs that can interfere with clinic workflow and patient care. IHSSPs may reduce clinic burden by helping patients access, afford, and remain on therapy.
Keyphrases
- healthcare
- end stage renal disease
- primary care
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- mental health
- prognostic factors
- systematic review
- depressive symptoms
- physical activity
- emergency department
- computed tomography
- magnetic resonance imaging
- risk factors
- skeletal muscle
- metabolic syndrome
- bone marrow
- neural network